Esophageal adenocarcinoma (EAC) is a lethal cancer that can develop from the premalignant condition, Barrett's esophagus. Little progress has been made in improving the survival rate for EAC patients; thus, an improved understanding of the genetic alterations driving EAC development is essential to improve patient prognosis.
Statement of Translational Relevance
Esophageal adenocarcinoma (EAC) is a lethal cancer that can develop from the premalignant condition, Barrett's esophagus. Little progress has been made in improving the survival rate for EAC patients; thus, an improved understanding of the genetic alterations driving EAC development is essential to improve patient prognosis.
We employed an integrative genomics approach to identify novel genes involved in EAC tumorigenesis that may serve as clinical markers. We identified RFC3 as a candidate oncogene activated by DNA amplification in ~25% of EAC patients. Knockdown of this gene inhibited cancer cell lines with amplification, but had little effect on cancer cell lines without the alteration or non-malignant cells. Furthermore, high RFC3 expression was associated with poor patient outcome in multiple epithelial cancer types. Our findings suggest that activation of RFC3 may play a role in EAC development and that its expression could serve as a prognostic marker.
Introduction
Over the past three decades there has been a dramatic rise in the incidence of esophageal adenocarcinoma (EAC) especially in Western countries (1, 2). However, progress in early detection and treatment strategies have been unable to improve the poor five-year survival rate of 16% (3). Barrett's esophagus (BE) is a premalignant condition that can give rise to EAC.
Histologically, BE is characterized by the replacement of the stratified squamous epithelium of lower esophagus with a metaplastic columnar epithelium (4) . Larger length of the Barrett's segment may be associated with higher risk of progression to EAC, and there is preliminary evidence to support that genomic instability is a marker for BE progression (4, 5) . Improved knowledge of EAC cancer biology and the identification of markers of progression in BE could significantly improve patient prognosis by invoking early interventions.
To discover genes involved in cancer progression, we identified recurrent genetic alterations in EAC tumors and assessed their presence in BE. Analysis of over 80 EAC tumors revealed RFC3
(Replication Factor C-3 at chromosome 13q13), a gene involved in DNA replication and cell proliferation, to be frequently amplified in EAC tumors. RFC3 amplification was also detected in the BE of a patient, suggesting it could be an early event in tumorigenesis. Furthermore, we showed that RFC3 gain is prevalent in several types of cancer, knockdown of RFC3 has an antiproliferative effect, and that RFC3 expression is associated with poor prognosis in multiple patient cohorts, which collectively suggests an oncogenic role for RFC3.
Materials and Methods

Discovery set (University of Michigan) tissue accrual and processing
Research. The discovery set includes 20 EACs, 10 matched BE tissue and 6 non-malignant esophagus tissue samples corresponding to the 10 BEs (Supplemental Table 1 ). An additional set of 65 EAC tumor specimens was collected for validation (Supplemental Table 1 ). All samples were collected (fresh-frozen in liquid nitrogen and stored at -80°C) with written patient consent and according to the ethics guidelines of the University of Michigan Institutional Review Board from radiation and chemotherapy naïve patients who underwent esophagectomy for adenocarcinoma at the University of Michigan Health System between 1991 and 2004. DNA and RNA were isolated from microdissected tissue that contained at least 70% tumor cell or Barrett's metaplasia content (for more details, see Supplemental Methods).
Array comparative genomic hybridization (aCGH) and GISTIC analysis for altered regions
20 EACs, 10 matched BE cases, and 6 non-malignant esophageal tissues were profiled as previously described (6, 7) . The EAC profiles were analyzed using the GISTIC (Genomic Identification of Significant Targets in Cancer) algorithm for copy number alteration frequency and amplitude, using the following parameters: q-value threshold of 0.10, refgene file Hg18, amplification threshold 0.1, deletion threshold 0.1, join segment size = 2 (8). CNAs were filtered for natural copy number variants within the GISTIC analysis (9) . High level copy number amplifications and deletions were defined as DNA segments with log2 ratios > 0.8 or log2 ratios 7 in Supplemental Methods and Supplemental Table 2 . RFC3 copy number status was also assessed by genomic DNA qPCR for the esophageal cell lines OE33, Flo-1, and Het-1a.
Gene expression profiling
Gene expression profiles for 11 of the 20 discovery set EAC tumors were generated using Affymetrix U133A expression arrays as previously described (Supplemental Tables 1 and 3) (10). Expression arrays were performed by the University of Michigan Microarray Core. The probe displaying the maximum average intensity across the 11 samples was used to assess gene expression when multiple probes for the same gene were present as previously described (10) .
Externally generated SNP, CGH, and expression data
Additional array data were accessed from publically available sources to investigate RFC3 in external cohorts (Supplemental Figure 1 , Supplemental Table 3 ). Data analyses performed on these datasets are described in Supplemental Methods.
Integration of DNA copy number and gene expression data
Spearman's correlation and Mann Whitney U tests conducted using MATLAB software were used to investigate whether increased gene dosage influenced expression for the four 13q13 amplicon genes. A correlation coefficient > 0.6 and p-values < 0.05 were considered significant.
Cell culture and shRNA-mediated RFC3 knockdown
Esophageal adenocarcinoma cell lines, OE33 (Sigma-Aldrich 96070808-1VL) and OE19 (Sigma-Aldrich 96071721-1VL), and breast ductal adenocarcinoma cell line, HCC1395 (ATCC CRL-2324), were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum and 0.1% Penicillin-Streptomycin (Invitrogen). Flo-1, also an EAC line, and Het-1a, a nonmalignant esophageal cell line, were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 10x Antibiotic-Antimycotic (Invitrogen 15240-096). DNA was isolated using standard phenol:chloroform extractions and RNA was extracted using Trizol reagent (Invitrogen). PLKO plasmid constructs containing shRNAs targeting RFC3 were purchased from Open Biosystems (Huntsville, AL; Catalog RHS4533-NM_181558). Lentiviral production and infections were performed as previously described (11) . RFC3 knockdown was quantified by qRT-PCR using TaqMan gene expression assays for RFC3 (Hs00161357_m1) with 18S rRNA (Hs99999901_s1) as an endogenous control (11) . Four shRNAs designed to target RFC3 were tested and the one giving the greatest RFC3 mRNA knockdown (R2 -TRCN0000072649) was used for cell model experiments. Knockdowns were also measured by Western blotting, as described in Supplemental Methods.
MTT cell proliferation assay
OE33, OE19, HCC1395, Flo-1 and Het-1a cell lines were stably transduced with shRNA targeting RFC3 and were investigated for differences in cell proliferation rates using the MTT assay (Trevigen, Gaithersburg, MD) as previously described (11) . Vector only lines (OE33-PLKO, OE19-PLKO, HCC1395-PLKO, Flo-1-PLKO, Het-1a-PLKO) served as controls to assess proliferation in the knockdown lines (OE33-R2, OE19-R2, HCC1395-R2, Flo-1-R2, Het1a-R2). Assay details are further described in Supplemental Methods.
Colony Formation Assay
Anchorage independent growth was assessed in stably transfected OE33, OE19, HCC1395, Flo-1 and Het-1a PLKO and RFC3 knockdown cell lines by the soft agar method as previously described (11) . Cells were plated at a density of 1000 cells/well in supplemented media containing 0.3% low melting point agarose. Each cell line was seeded in triplicate and cultured for 2 (OE33 and Het-1a) or 3 weeks (HCC1395, OE19, Flo-1) at 37°C in 5% CO2. Colonies were stained with MTT, counted, and the mean ± SEM were normalized to the average of control (PLKO) cells.
Survival analysis
Gene expression and patient survival data for six independent tumor datasets were obtained including one EAC, one breast cancer, and four lung cancer datasets (Supplemental Table 3 ).
For each dataset, patients were grouped into tertiles based on expression levels (i.e. low, middle, and high) and survival times of patients with expression values in the lowest tertile were compared to those of patients whose expression ranked in the highest tertile. Survival associations were tested for RFC3, PDS5B, KL, and STARD13. Log-rank Mantel-Cox tests were performed and Kaplan-Meier survival curves were generated using GraphPad Prism 5 software to assess RFC3 expression associations with patient survival. A p-value < 0.05 was considered significant. Multivariate analyses were performed using the Robust Likelihood-Based Survival Modeling package in R (rbsurv) (12) as described in Supplemental Methods.
Results
Identification of significant regions of copy number alteration in EAC
We generated tiling resolution CGH profiles for a discovery set of 20 EAC tumors. Table 4 . We identified several frequently reported EAC alterations, including gains of 7p, 8q, and 17q as well as losses of 3p, 5q, and 17p, demonstrating our tumors are consistent with the EAC genomic landscape (5, 13-21).
Investigation of amplified regions without known oncogenes
Research. Although both amplifications and deletions are known to be important in cancer development, the gain-of-function effect of gene amplifications makes them ideal targets for the development of biomarkers and strategies for therapeutic intervention. Thus, we chose to focus our study on DNA amplifications, as they are a prominent mechanism of oncogene activation (7) . In total, 9 of the 11 regions in Figure 1 can be attributed to known oncogenes in EAC or other tumor types, such as MYC, ERBB2, and EGFR. Driver oncogenes for the 7q21.11 and 13q13.1 regions remain elusive despite frequent reporting of DNA amplifications on 7q and 13q in EAC copy number studies. In our discovery set, high level amplifications of 13q13 were more prevalent than amplifications of 7q21; thus, we focused on the 13q13 amplicon which contained only four genes: PDS5B, KL, STARD13, and RFC3 ( Figure 2 ).
Copy number and gene expression integration for 13q13 genes
Next, we sought to identify the driver gene of 13q13 amplification in EAC. originating from the same patient ( Figure 3B -E) (22) . RFC3 was the only gene differentially expressed between non-malignant and EAC tumor tissues (p<0.05). Analyses of ours and externally generated data revealed RFC3 as the only 13q13 amplified gene that exhibited a strong correlation between gene dosage and expression and differential expression in tumors relative to non-malignant tissue. Thus, we concluded that RFC3 is the driver gene of the 13q13 amplicon, and a novel candidate oncogene in EAC development.
RFC3 amplification is a prevalent feature of EAC tumors
To validate our array CGH data, we performed qPCR on genomic DNA for each EAC tumor in the discovery set. A strong correlation between qPCR gene dosage and moving average array CGH log2 ratios was observed for RFC3 (r=0.81, p < 0.05) validating our array CGH findings (Supplemental Table 5 ). To investigate the prevalence of RFC3 amplification, we performed genomic qPCR to assess gene copy number in an additional set of 65 EAC tumors. DNA copy number gain, defined as greater than 1.6-fold increase in gene dosage relative to normal (diploid) tissue, was observed in 22 of 85 (26%) samples. High-level amplification of RFC3, defined as greater than 2-fold increase in gene dosage relative to normal (diploid) tissue, was observed in the 19% of tumors. We also assessed RFC3 copy number status in a publically available dataset (GSE22524), which showed RFC3 was gained or amplified in 2 of 7 of EACs. Lastly, we looked for RFC3 amplification in BE samples obtained from the same patients in the discovery set, whose tumors we profiled with array CGH (Supplemental Table 1 ). In the 10 EAC cases that had corresponding BE samples examined, one (10%) harbored RFC3 amplification. RFC3 was amplified in both the tumor and corresponding BE tissue, indicating it may play a role in the progression of BE to EAC (Figure 4 ). These findings demonstrate RFC3 DNA amplification is prevalent in a broad spectrum of EAC tumors and is not limited to our study. 
RFC3 is a broad-spectrum oncogene amplified in cancers from tissues of diverse origin
Because a number of established oncogenes are activated in a broad spectrum of cancer tissues, we investigated whether RFC3 was altered in cancers other than EAC. To address this question we analyzed copy number data for over 700 cancer cell lines spanning 31 different tissue types.
RFC3 copy number gain (defined as >2 copies) was detected in 14% of all cases in 23 tissue types, while 6% of all malignancies harbored gains of >3 copies. A variety of cancer tissues, most of which were epithelial in origin, displayed elevated RFC3 gene dosage (Supplemental Figure 3A) . Interestingly, RFC3 gains were most prevalent in cancers of the large intestine and esophagus, further supporting our findings. Similar to EAC tumors, cell lines harboring RFC3 copy number gains showed higher expression than those without gain (p<0.0001) (Supplemental Figure 3B ).
Knockdown of RFC3 inhibits proliferation and anchorage independent growth
To assess the functional role of RFC3 in esophageal tumorigenesis, we conducted shRNAmediated RFC3 knockdown. Array CGH for the commonly used EAC model cell line, OE33, revealed a 13q13 DNA amplification encompassing RFC3 (Supplemental Figure 4A) . We confirmed the presence of RFC3 DNA amplification in OE33 by analyzing additional copy number profiles independently generated using SNP arrays by the Wellcome Trust Sanger Institute and GlaxoSmithKline (Supplemental Figure 4A) and by genomic DNA qPCR (data not shown). Knockdowns were also performed in additional esophageal adenocarcinoma cell lines, OE19 (RFC3 gain, data not shown) and Flo-1 (no gain of RFC3, data not shown), as well as Het1a, a non-malignant esophageal line (no gain of RFC3, data not shown). Consistent with the copy number status, cell lines with increased gene dosage also displayed higher expression of RFC3 as determined by qPCR (Supplemental Figure 5) 
oncogenic role, OE33 and OE19 (lines harboring RFC3 gains) would be dependent on RFC3 expression, and that knockdown would result in a reduction in cell proliferation and anchorage independent growth, while Flo-1 and Het-1a, which lack RFC3 copy number gains, would not be affected.
Four separate shRNAs designed to target RFC3 were tested, and the one that consistently demonstrated the greatest knockdown (R2) was used for all subsequent experiments (Methods, Supplemental Figure 6 ). Indeed, we observed a significant reduction in cell proliferation and anchorage independent growth in both OE33 and OE19 R2-knockdown lines relative to the vector only control lines (Figures 5A, 5B, 5C and 5D, Supplemental Figures 7 and 8) , and minimal to no effect in Flo-1 EAC and non-malignant Het-1a cells ( Figures 5A, 5B , 5F and 5G, Supplemental Figures 7 and 8 ). Growth inhibition in OE33 was also seen using the second best hairpin (R3) -albeit to a lesser degree than R2, consistent with the lower level of knockdownreducing the probability of off-target effects (Supplemental Figure 9) . To determine if RFC3 functions as a putative oncogene in other cancer types, we also inhibited RFC3 in the breast cancer cell line, HCC1395, which harbored RFC3 DNA copy number gain (Supplemental Figure   4B ). Knockdown of RFC3 resulted in similar reductions in expression, cell proliferation, and colony formation in HCC1395 (Figures 5A, 5B and 5E, Supplemental Figure 8 ). These cell experiments supported our hypothesis, demonstrating a significant biological effect of RFC3 knockdown in cancer cells, consistent with an oncogenic role for RFC3 in cancer.
Overexpression of RFC3 is associated with increased cell growth and proliferation pathways
In an attempt to elucidate gene networks and biological pathways to which RFC3 belongs, we performed a Significance Analysis of Microarrays (SAM) analysis on a panel of EAC tumors (Supplemental Methods and Supplemental 
negatively correlated with that of RFC3 (Supplemental Table 6 ). These genes were investigated using Ingenuity Pathway Analysis software to determine whether they were enriched for any annotated cell pathways or functions. Applying this strategy, we revealed these genes were enriched in cell growth and proliferation and DNA replication, recombination and repair networks (Supplemental Table 7 ). Moreover, these genes were enriched for involvement in the Wntɴ-catenin signaling pathway. These findings validate the known functional involvement of RFC3 in DNA replication and implicate RFC3 in cancer promoting pathways and networks, providing additional evidence to support our hypothesis that RFC3 is an important oncogene in cancer.
High RFC3 mRNA levels are associated with poor patient survival
As a final assessment of the importance of increased RFC3 copy number in EAC biology, we sought to determine whether RFC3 gene expression was associated with patient survival in publically available expression data for 48 EAC tumors (23) . Since RFC3 was gained/amplified in ~25-35% of tumors (~25% from qPCR of all 85 samples, ~35% from CGH in the initial discovery set), and this subset of tumors also demonstrated the highest expression of the gene, we segregated the samples by RFC3 expression into tertiles based on the assumption that the highest expressers would likely represent the cases with RFC3 gain/amplification. We then compared survival between the top and bottom patient tertiles (see Methods). Although the association did not reach statistical significance, a trend towards poorer survival in patients with higher RFC3 expression was evident (p=0.1565) ( Figure 6A ). We also assessed associations between STARD13, KL, and PDS5B expression with patient survival in this EAC cohort. Consistent with our data that RFC3 is the driver of 13q13 amplification, RFC3 expression had the strongest association with patient survival in EAC. Since the small sample size of EAC tumors may have prevented a significant association with patient survival in EAC and we observed RFC3 amplification in other cancer types including lung and breast, we interrogated five additional datasets to determine whether RFC3 expression was associated with patient survival. Comparison of survival times in patients with high versus low expression in 295 breast cancers and four independent sets of lung adenocarcinoma (n=58, n=82, n=107 and n=92) revealed survival was significantly worse in patients with high RFC3 expression in the breast cancer (p=0.0027) and two of four lung adenocarcinoma sets (p=0.0079 and p=0.0102) (Figure 6 B-D). The same trend was evident in the two other lung datasets (p=0.0603 and p=0.0653). Of the four genes we identified in the 13q13 amplicon, RFC3 had the strongest association with patient survival in each cohort assessed except for one lung adenocarcinoma dataset, where STARD13 had the strongest association with patient survival (p=0.0136).
Lastly, we aimed to determine the prognostic performance of RFC3 in relation to other known oncogenes targeted by amplification in EAC. For this purpose, we performed Robust Likelihood-Based Survival Modeling ((12), see Supplemental Methods) using RFC3 along with the known driver genes of nine other significantly amplified regions identified in the EAC
samples (MYB, EGFR, MET, MYC, CCND1, KRAS, ERBB2, GATA6 and CCNE1). This method
selects survival-associated genes based on the partial likelihood of the Cox model and can discover multiple sets of genes by iterative forward selection. When applied to the same five datasets described above, we found that RFC3 was part of a selected model for three of these datasets (Supplemental Table 8 ). RFC3 and MYC were the amplified oncogenes that most consistently contributed to a prognostic model across the datasets, suggesting that RFC3 may indeed be useful from a prognostic standpoint. Together, the association of RFC3 expression and EGFR (24, 25) . CNAs in EAC tumors have been studied using a variety of detection methods with various resolutions including conventional CGH, microsatellite mapping, array CGH and SNP arrays (4). The goal of these studies has generally been to identify the targeted driver genes of CNAs, as they are postulated to have causal roles in EAC tumorigenesis.
Findings from copy number profiling studies in EAC have resulted in the compilation of a wellestablished genomic landscape of EAC; recurrent genomic events include gains of 7p, 8q, and 17q and losses of 3p, 4p, 5q, and 17p (26) (27) (28) (29) (30) (31) . Most recurrently altered regions in EAC contain candidate or proven oncogenes or tumor suppressors such as MYC, EGFR, CDKN2A and TP53, however, the driver genes for some frequently altered regions have yet to be discovered.
In the current study we identified and investigated a frequently amplified region of DNA located on chromosome 13q13. Recurrent DNA amplification of this region was initially identified in a discovery set of 20 EAC tumors and was validated in the discovery set and an additional 65 EAC tumors. 13q copy number gains are frequently reported in EACs, including several recent high resolution studies, although no driver gene has been conclusively identified (5, 21, 26-28, 30, 32) . This could reflect the fact that 13q DNA gains are often large, segmental alterations encompassing hundreds of genes, making the elucidation of target genes difficult. Our analysis detected a discrete, minimal common region of DNA amplification in an EAC tumor and RFC3, replication factor C 3, is one of five replication factor subunits that form of a multiprotein complex known as Activator 1, which is required for DNA replication and repair by the DNA polymerases İ and į. Collectively, the RFC complex acts as a clamp loader, enabling binding of the proliferating cell nuclear antigen (PCNA) clamp onto primed DNA (33) . PCNA is required for processive elongation during DNA synthesis, emphasizing the importance of RFC3 in cell proliferation due to its role in DNA replication (33) . Human replication factor C genes are highly homologous to RFC genes in yeast, and RFC3 is essential for growth in fission yeast (34, 35) . In human cells, RFC3 protein was found associated with the mitogenic transcription factor, MYC, which suggests RFC3 could have an integral role in driving cell proliferation in human cells as well and could explain the anti-proliferative knockdown effect we observed in cancer cells (36) .
Interestingly, RFC3 expression is regulated by several transcription factors encoded by genes with established roles in cancer. MYCN and SHH, two proteins that promote proliferation in cancer cells, increase RFC3 expression levels while tumor suppressors, TP53 and CDKN2A, suppress RFC3 expression (37) (38) (39) (40) . Expression analysis in a cohort of 52 EACs corroborated these findings, as RFC3 expression was negatively correlated with P53 expression and positively correlated with SHH expression, although the fold change in P53 and SHH expression between high and low expressing RFC3 tumors did not reach our two-fold criteria for pathway analysis.
The transcription factors E2F1 and E2F4, which induce transition of cells from G1 to S phase in the cell cycle thereby promoting DNA replication, are also known to bind the RFC3 gene 
promoter, suggesting they could positively regulate RFC3 (41) . Pathway analysis on genes whose expression was associated with RFC3 expression revealed an enrichment of genes in the Wnt/ɴ-catenin signaling pathway, which stimulates the transcription of proliferation stimulating genes, as well as gene networks involved in cellular growth and proliferation and DNA replication, recombination and repair. Induction by oncogenes and negative regulation by tumor suppressors, in addition to the involvement of RFC3 in cell pathways and networks with roles in cell proliferation are consistent with a cancer-promoting role for RFC3. Considering these findings, we hypothesize RFC3 functions as an oncogene by driving proliferation and enabling continuous expansion of cancer cells.
Other replication factor C genes have also been implicated in tumorigenesis. RFC4 upregulation was discovered in hepatocellular carcinoma (HCC) tissues relative to non-malignant liver tissue, and knockdown of endogenous RFC4 decreased cellular proliferation, increased apoptosis, and enhanced the chemosensitivity of the HCC cell line HepG2 (42) . Moreover, RFC4 appears to be overexpressed in cancer cells from the lung, prostate, colon, stomach and skin relative to tissue-matched non-malignant cells (43) . Importantly, RFC4 was one of several genes whose expression was up-regulated in response to SV40 immortalization in lung fibroblasts, implicating the replication factor C complex in one of the earliest and essential steps in malignant transformation (43) . RFC2 is overexpressed in nasopharyngeal carcinoma and was also found associated with the oncogenic protein c-MYC, while RFC5 is up-regulated in human papillomavirus-positive squamous cell carcinomas of the head and neck (36, 44, 45) . Thus, there is abundant evidence implicating replication factor C genes in tumorigenesis and our study has colorectal cancers (46) . The findings of this study and ours suggest RFC3 may act in a tissue specific manner in the context of cancer.
We validated the biological effect of RFC3 up-regulation in cell model experiments by showing that RFC3 suppression impedes cell proliferation and anchorage independent growth exclusively in cancer cell lines with copy gain, an observation consistent with our oncogene hypothesis.
Although knockdown of RFC3 was less pronounced in the non-malignant esophageal line Het-1a as compared to all other lines (50% vs ~75-90%), even a 50% reduction in mRNA expression would be expected to cause a phenotypic effect. We are therefore confident in our observation that knockdown of RFC3 has no significant effect on the growth of non-malignant esophageal cells.
We were also interested in when RFC3 becomes involved during EAC development. Our unique dataset allowed us to screen pre-neoplastic, BE tissues from individuals who progressed to develop EAC. We asked if RFC3 DNA amplification was present in any of the BE tissues of patients who developed EAC, based on the hypothesis that if present in pre-neoplastic tissue, RFC3 amplification could be an early, causal event in EAC development. Intriguingly, we observed a high level, focal DNA amplification encompassing RFC3 in one of the BE samples whose corresponding tumor also harbored the DNA alteration (Figure 4) . However, areas of dysplasia are present in many BE from patients with EAC and we cannot confirm whether the only area showing increased copy number were from dysplastic or non-dysplastic cells in this specimen. Therefore, we interpret this finding with caution and conclude that further investigation in BE samples is required to confirm whether or not RFC3 DNA amplification is an early event in EAC tumorigenesis. Although genomic data on premalignant BE samples are rare, a segmental copy number gain of 13q was also identified in a BE case in the study by Akagi et al 21) , demonstrating the 13q amplicon we observed may be a recurrent event not only in EAC, but also in its BE precursors. The observation of RFC3 amplification and 13q copy number gain in BE samples of our own and from external datasets points to the significance of this alteration.
These findings suggest RFC3 amplification may have a role early in the development of EAC and that amplification could potentially be a marker of BE progression to EAC; however, we emphasize that a large prospective cohort is needed to investigate the significance of RFC3 amplification in BE samples.
Lastly, we demonstrated that RFC3 DNA copy number alterations are not restricted to EAC but are also prevalent in other cancers (Supplemental Figure 3A) . Moreover, high RFC3 expression was associated with poor patient survival in multiple lung and breast adenocarcinoma datasets, as well as in EACs. Taken together, our data provide multifaceted evidence that RFC3 is a candidate oncogene with potential predictive and prognostic implications in addition to its biological significance in EAC development, and perhaps, in other malignancies as well.
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